Percutaneous thermal ablation for cT1 renal mass in solitary kidney: A multicenter trifecta comparative analysis versus robot-assisted partial nephrectomy.


Journal

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
ISSN: 1532-2157
Titre abrégé: Eur J Surg Oncol
Pays: England
ID NLM: 8504356

Informations de publication

Date de publication:
02 2023
Historique:
received: 04 07 2022
revised: 20 09 2022
accepted: 29 09 2022
pubmed: 11 10 2022
medline: 3 3 2023
entrez: 10 10 2022
Statut: ppublish

Résumé

Renal cell carcinoma (RCC) in solitary kidney (SK) represents a challenging scenario. We sought to compare outcomes of robot-assisted partial nephrectomy (RAPN) versus percutaneous thermal ablation (PTA) in SK patients with renal tumors cT1. We performed a multicenter retrospective analysis of SK patients treated for RCC. The PTA group included cryoablation or radiofrequency ablation. We collected baseline characteristics, intraoperative, pathological, and post-operative data. We applied an arbitrary composite "trifecta" to assess surgical, functional, and oncological outcomes, only for malignant histology. RFS analysis was performed using the Kaplan-Meier method. Multivariable regression analysis was performed to determine independent predictors of "trifecta" achievement. We included 198 SK patients (RAPN, n = 50; PTA n = 119). Mean clinical tumor size was not significantly different while R.E.N.A.L. score was higher for RAPN (p < 0.001). No differences in intra and major post-procedural complications. Recurrence rate was higher in PTA group but not statistically significant (p < 0.328). No difference in metastasis rate was found (p = 0.435). RFS was 96.1% in RAPN and 86.8% in PTA cohort (p = 0.003) while no difference in PFS was detected (p = 0.1). Trifecta was achieved in 72.5% of RAPN vs 77.3% of PTA (p = 0.481). Multivariable analysis has not detected predictors for Trifecta achievement. PTA offers good outcomes in the management of SK patients with RCC. Compared with RAPN, it might carry a higher risk of recurrence; on the other hand, re-treatment is possible. Overall, PTA can be safely offered to treat SK patients presenting RCC. In general, it should be preferred in more frail patients to minimize the risk of complications.

Identifiants

pubmed: 36216659
pii: S0748-7983(22)00692-8
doi: 10.1016/j.ejso.2022.09.022
pii:
doi:

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

486-490

Informations de copyright

Copyright © 2022 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Auteurs

Savio Domenico Pandolfo (SD)

Division of Urology & Massey Cancer Center, VCU Health, Richmond, VA, USA; Department of Neurosciences, Reproductive Sciences and Odontostomatology, Urology Unit, University of Naples "Federico II", Napoli, Italy. Electronic address: ricautor@gmail.com.

Davide Loizzo (D)

Division of Urology & Massey Cancer Center, VCU Health, Richmond, VA, USA; Department of Emergency and Organ Transplantation-Urology, Andrology and Kidney Transplantation Unit, University of Bari, Bari, Italy.

Alp T Beksac (AT)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.

Ithaar Derweesh (I)

Department of Urology, University of California San Diego School of Medicine, La Jolla, CA, USA.

Antonio Celia (A)

Department of Urology, San Bassano Hospital, Bassano Del Grappa, Italy.

Lorenzo Bianchi (L)

Division of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Jeffrey Elbich (J)

Department of Radiology, Vascular Interventional Radiology, VCU Health, Richmond, VA, USA.

Giovanni Costa (G)

Department of Urology, San Bassano Hospital, Bassano Del Grappa, Italy.

Umberto Carbonara (U)

Division of Urology & Massey Cancer Center, VCU Health, Richmond, VA, USA.

Giuseppe Lucarelli (G)

Department of Emergency and Organ Transplantation-Urology, Andrology and Kidney Transplantation Unit, University of Bari, Bari, Italy.

Clara Cerrato (C)

Department of Urology, University of California San Diego School of Medicine, La Jolla, CA, USA.

Margaret Meagher (M)

Department of Urology, University of California San Diego School of Medicine, La Jolla, CA, USA.

Pasquale Ditonno (P)

Department of Emergency and Organ Transplantation-Urology, Andrology and Kidney Transplantation Unit, University of Bari, Bari, Italy.

Lance J Hampton (LJ)

Division of Urology & Massey Cancer Center, VCU Health, Richmond, VA, USA.

Giuseppe Basile (G)

Department of Urology, San Raffaele Scientific Institute, Milan, Division of Experimental Oncology/Unit of Urology, URI, IRCCS San Raffaele Hospital, Milan, Italy.

Fernando J Kim (FJ)

Division of Urology, Denver Health, Denver, CO, USA.

Riccardo Schiavina (R)

Division of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Umberto Capitanio (U)

Department of Urology, San Raffaele Scientific Institute, Milan, Division of Experimental Oncology/Unit of Urology, URI, IRCCS San Raffaele Hospital, Milan, Italy.

Jihad Kaouk (J)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.

Riccardo Autorino (R)

Division of Urology & Massey Cancer Center, VCU Health, Richmond, VA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH